Folic Acid Supplementation to Prevent Recurrent Neural Tube Defects

4 Milligrams Is Too Much

Cara D. Dolin, Andrea Deierlein, Mark I. Evans

Research output: Contribution to journalArticle

Abstract

Some medical practices have been ingrained in custom for decades, long after "proof" that they were effective was established. It is necessary to periodically reevaluate these practices, as newer theories and research may challenge the evidence upon which they were based. An example is the decades' old practice of recommending a 4-mg (4,000-μg) supplement of folic acid to women who are at risk for recurrent neural tube defect (NTD) during pregnancy. This recommendation was based on findings from a randomized clinical trial in 1991. Since then, multiple studies have confirmed the utility of 400-800 μg of folic acid in lowering both primary and recurrent risks of NTDs, but no studies have established any further reduction in risk with doses over 1 mg. Current understanding of folic acid metabolism during pregnancy suggests that at higher doses, above ∼1 mg, there is not increased absorption. Recent evidence suggests that 4 mg folic acid supplementation may not be any more effective than lower doses for the prevention of recurrent NTDs. Thus, we recommend that it is time for clinicians to reexamine their reliance on this outdated recommendation and consider using current recommendations of 400-800 μg per day for all patients in conjunction with assessment of maternal folate status.

Original languageEnglish (US)
JournalFetal Diagnosis and Therapy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Neural Tube Defects
Folic Acid
Pregnancy
Risk Reduction Behavior
Randomized Controlled Trials
Mothers
Research

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Radiology Nuclear Medicine and imaging
  • Obstetrics and Gynecology

Cite this

Folic Acid Supplementation to Prevent Recurrent Neural Tube Defects : 4 Milligrams Is Too Much. / Dolin, Cara D.; Deierlein, Andrea; Evans, Mark I.

In: Fetal Diagnosis and Therapy, 01.01.2018.

Research output: Contribution to journalArticle

@article{b1c853a9b062407b9cd2aa9a4db1b43a,
title = "Folic Acid Supplementation to Prevent Recurrent Neural Tube Defects: 4 Milligrams Is Too Much",
abstract = "Some medical practices have been ingrained in custom for decades, long after {"}proof{"} that they were effective was established. It is necessary to periodically reevaluate these practices, as newer theories and research may challenge the evidence upon which they were based. An example is the decades' old practice of recommending a 4-mg (4,000-μg) supplement of folic acid to women who are at risk for recurrent neural tube defect (NTD) during pregnancy. This recommendation was based on findings from a randomized clinical trial in 1991. Since then, multiple studies have confirmed the utility of 400-800 μg of folic acid in lowering both primary and recurrent risks of NTDs, but no studies have established any further reduction in risk with doses over 1 mg. Current understanding of folic acid metabolism during pregnancy suggests that at higher doses, above ∼1 mg, there is not increased absorption. Recent evidence suggests that 4 mg folic acid supplementation may not be any more effective than lower doses for the prevention of recurrent NTDs. Thus, we recommend that it is time for clinicians to reexamine their reliance on this outdated recommendation and consider using current recommendations of 400-800 μg per day for all patients in conjunction with assessment of maternal folate status.",
author = "Dolin, {Cara D.} and Andrea Deierlein and Evans, {Mark I.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000491786",
language = "English (US)",
journal = "Fetal Diagnosis and Therapy",
issn = "1015-3837",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Folic Acid Supplementation to Prevent Recurrent Neural Tube Defects

T2 - 4 Milligrams Is Too Much

AU - Dolin, Cara D.

AU - Deierlein, Andrea

AU - Evans, Mark I.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Some medical practices have been ingrained in custom for decades, long after "proof" that they were effective was established. It is necessary to periodically reevaluate these practices, as newer theories and research may challenge the evidence upon which they were based. An example is the decades' old practice of recommending a 4-mg (4,000-μg) supplement of folic acid to women who are at risk for recurrent neural tube defect (NTD) during pregnancy. This recommendation was based on findings from a randomized clinical trial in 1991. Since then, multiple studies have confirmed the utility of 400-800 μg of folic acid in lowering both primary and recurrent risks of NTDs, but no studies have established any further reduction in risk with doses over 1 mg. Current understanding of folic acid metabolism during pregnancy suggests that at higher doses, above ∼1 mg, there is not increased absorption. Recent evidence suggests that 4 mg folic acid supplementation may not be any more effective than lower doses for the prevention of recurrent NTDs. Thus, we recommend that it is time for clinicians to reexamine their reliance on this outdated recommendation and consider using current recommendations of 400-800 μg per day for all patients in conjunction with assessment of maternal folate status.

AB - Some medical practices have been ingrained in custom for decades, long after "proof" that they were effective was established. It is necessary to periodically reevaluate these practices, as newer theories and research may challenge the evidence upon which they were based. An example is the decades' old practice of recommending a 4-mg (4,000-μg) supplement of folic acid to women who are at risk for recurrent neural tube defect (NTD) during pregnancy. This recommendation was based on findings from a randomized clinical trial in 1991. Since then, multiple studies have confirmed the utility of 400-800 μg of folic acid in lowering both primary and recurrent risks of NTDs, but no studies have established any further reduction in risk with doses over 1 mg. Current understanding of folic acid metabolism during pregnancy suggests that at higher doses, above ∼1 mg, there is not increased absorption. Recent evidence suggests that 4 mg folic acid supplementation may not be any more effective than lower doses for the prevention of recurrent NTDs. Thus, we recommend that it is time for clinicians to reexamine their reliance on this outdated recommendation and consider using current recommendations of 400-800 μg per day for all patients in conjunction with assessment of maternal folate status.

UR - http://www.scopus.com/inward/record.url?scp=85052747831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052747831&partnerID=8YFLogxK

U2 - 10.1159/000491786

DO - 10.1159/000491786

M3 - Article

JO - Fetal Diagnosis and Therapy

JF - Fetal Diagnosis and Therapy

SN - 1015-3837

ER -